Prevalence of Stress Urinary Incontinence in Obese Versus Non-obese Nulligravid Women

NCT ID: NCT05845320

Last Updated: 2023-05-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

200 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-05-14

Study Completion Date

2023-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Urinary incontinence (UI) is more common than any other chronic disease. Stress urinary incontinence (SUI), among the various forms of urinary incontinence, is the most prevalent (50%) type of this condition. Female urinary continence is maintained through an integrated function of pelvic floor muscles (PFMs), fascial structures, nerves, supporting ligaments, and the vagina. In women with SUI, the postural activity of the PFMs is delayed, and the balance ability is decreased. Many women, by learning the correct timing of a pelvic floor contraction during a cough, are able to eliminate consequent SUI. Timing is an important function of motor coordination and could be affected by proprioception.

We aim to assess stress urinary incontinence in obese and non-obese Nulligravid females.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Stress Urinary Incontinence

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Obese

BMI\>30

ICIQ-UI SF questionnaire

Intervention Type OTHER

validated arabic short form of ICIQ on urinary incontinence

Non-obesse

BMI\<25

ICIQ-UI SF questionnaire

Intervention Type OTHER

validated arabic short form of ICIQ on urinary incontinence

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

ICIQ-UI SF questionnaire

validated arabic short form of ICIQ on urinary incontinence

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Women aged between18 and 45 years.
* Non obese females with BMI \<25kg/m2.
* Obese females with BMI ≥30kg/m2.
* Nulligravid females.

Exclusion Criteria

* Multiparous Females
* Patients with active urinary tract infection.
* Patients with respiratory or neurological diseases.
* Patients with communication problems, cognitive disorders \& mental disturbance.
* Current treatment with drugs (benzodiazepines, diuretics)
* Patients who underwent any previous abdominal or pelvic surgery.
Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Ain Shams University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Maii Nawara, MD

Role: PRINCIPAL_INVESTIGATOR

Associate professor

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Ain Shams University maternity hospital

Cairo, Cairo/القاهرة, Egypt

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Egypt

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Maii Nawara

Role: CONTACT

+201001848388

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Maii Nawara, MD

Role: primary

01001848388

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

MS 188/2023

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.